论文期刊

取消

高级检索

检索历史清除

首页> Addiction biology> A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.

A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.

导出 OA

翻译打印收藏纠错

作者： Jermaine D,Jones ^[1] ; Shanna,Babalonis ^[2] ; Ronald,Marcus ^[3] ; Bradley,Vince ^[4] ; Debra,Kelsh ^[4] ; Michelle R,Lofwall ^[2] ; Heather,Fraser ^[5] ; Blake,Paterson ^[6] ; Suky,Martinez ^[1] ; Diana M,Martinez ^[7] ; Edward V,Nunes ^[1] ; Sharon L,Walsh ^[1] ; Sandra D,Comer ^[2]

作者单位： Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA. ^[1] Department of Behavioral Science, Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky, USA. ^[2] Supernus Pharmaceuticals, Rockville, Maryland, USA. ^[3] Vince and Associates, Overland Park, Kansas, USA. ^[4] Cerecor Inc, Baltimore, Maryland, USA. ^[5] NRZ Consulting, Baltimore, Maryland, USA. ^[6] Translational Research Training Program in Addiction, City College of New York, New York City, New York, USA. ^[7]

关键词 CERC-501 kappa opioid receptor nicotine withdrawal smoking cessation

主题词成年人(Adult);情感(Affect);焦虑(Anxiety);苯甲酰胺类(Benzamides);交叉研究(Cross-Over Studies);双盲法(Double-Blind Method);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);麻醉品拮抗药(Narcotic Antagonists);尼古丁(Nicotine);烟碱激动剂(Nicotinic Agonists);吡咯烷类(Pyrrolidines);随机分配(Random Allocation);受体, 阿片样, κ(Receptors, Opioid, kappa);戒烟(Smoking Cessation);物质戒断综合征(Substance Withdrawal Syndrome);烟草对健康的危害(Tobacco Use Disorder)

DOI 10.1111/adb.12799

PMID 31240842

发布时间 2022-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Addiction biology

Addiction biology

2020年25卷4期

e12799页

相似文献

中文期刊
外文期刊
学位论文
会议论文

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷